Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis in the Main Trunk

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jul 30

PMID 39077472

Authors

Qi Liu

Ying Zhang

Jingwen Zhang

Luhao Chen

Yi Yang

Yan Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the efficacy and safety of mFOLFOX-based hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT).

Methods: This retrospective study included patients who received mFOLFOX-based HAIC combined with TKIs and ICIs from January 2021 to January 2023. The primary outcome was the objective response rate of PVTT response, and the secondary outcomes were 6-month, 1-year survival rate, overall survival (OS), and corresponding adverse events and complications were also evaluated. PVTT responses were assessed using ITK-SNAP software.

Results: A total of 37 patients were included in the analysis, 18.92% achieved a complete response and 56.76% achieved a partial response in PVTT response. The objective response rate (ORR) of PVTT was 75.68%. The 6-month survival rate was 89%, the 1-year survival rate was 66%, and the median OS was 15.8 months. In univariate analysis, Child-Pugh score (P=0.010) was important factor for predicting OS; in multivariate analysis, Child-Pugh score (P=0.015, HR= 3.089, 95%CI: 1.250-7.633) was the important factor for predicting OS. In terms of adverse reactions, the most common adverse reactions associated with HAIC are pain and thrombocytopenia associated with oxaliplatin.

Conclusion: FOLFOX-based HAIC combined with TKIs and ICIs induced an objective response rate of 75.68% in PVTT.

Clinical Signicance: FOLFOX-based HAIC combined with TKIs and ICIs provides more treatment options for PVTT.

References

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M . Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016; 46(5):372-90. DOI: 10.1111/hepr.12697. View

Lyu N, Lin Y, Kong Y, Zhang Z, Liu L, Zheng L . FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut. 2017; 67(2):395-396. DOI: 10.1136/gutjnl-2017-314138. View

Greten T, Abou-Alfa G, Cheng A, Duffy A, El-Khoueiry A, Finn R . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021; 9(9). PMC: 8438858. DOI: 10.1136/jitc-2021-002794. View

. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2017; 117(5):381-403. DOI: 10.1016/j.jfma.2017.09.007. View

Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N . Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018; 3(6):424-432. DOI: 10.1016/S2468-1253(18)30078-5. View

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

Farias Gomes A, Brasil D, Silva A, Freitas D, Haiter-Neto F, Groppo F . Accuracy of ITK-SNAP software for 3D analysis of a non-regular topography structure. Oral Radiol. 2019; 36(2):183-189. DOI: 10.1007/s11282-019-00397-y. View

Yin J, Bo W, Sun J, Xiang X, Lang J, Zhong J . New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017; 5(2):169-176. PMC: 5472938. DOI: 10.14218/JCTH.2016.00071. View

10.

Chen Z, Lin Z, Chen Y, Chen J, Chen J . Clinical efficacy of endovascular radiofrequency ablation in the treatment of portal vein tumor thrombus of primary hepatocellular carcinoma. J Cancer Res Ther. 2018; 14(1):145-149. DOI: 10.4103/jcrt.JCRT_784_17. View

11.

Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K . Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer. 2021; 10(2):151-160. PMC: 8077503. DOI: 10.1159/000513706. View

12.

Huang C, Zhu X, Shen Y, Wu D, Ji Y, Ge N . Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res. 2021; 9(1):19. PMC: 7981986. DOI: 10.1186/s40364-021-00274-z. View

13.

Yushkevich P, Pashchinskiy A, Oguz I, Mohan S, Schmitt J, Stein J . User-Guided Segmentation of Multi-modality Medical Imaging Datasets with ITK-SNAP. Neuroinformatics. 2018; 17(1):83-102. PMC: 6310114. DOI: 10.1007/s12021-018-9385-x. View

14.

Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S . Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021; 10(3):181-223. PMC: 8237791. DOI: 10.1159/000514174. View

15.

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

16.

Cabibbo G, Celsa C, Alimenti E, Iavarone M . Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon. Hepatology. 2023; 77(4):1074-1077. DOI: 10.1097/HEP.0000000000000205. View

17.

Chan S, Johnson P, Mo F, Berhane S, Teng M, Chan A . International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer. 2014; 33(10):481-91. PMC: 4198751. DOI: 10.5732/cjc.014.10133. View

18.

Sun H, Zhang M, Liu R, Liu Y, Hou Y, Wu C . Endovascular implantation of I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. Future Oncol. 2018; 14(12):1165-1176. DOI: 10.2217/fon-2017-0354. View

19.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

20.

Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y . Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2018; 69(1):60-69. DOI: 10.1016/j.jhep.2018.02.008. View